GlassScriptPhysician profile
Theresa Gray
NPI 1386025377
$3,749.53
in general payments reported to CMS, 2019-2025
32 companies · $444 in 2025
The $444 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $71.22 · 2021: $227 · 2022: $2,226 · 2023: $174 · 2024: $459 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,078.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $1,478.08 | 2022 | |
| Depuy Synthes Sales INC. | $482.20 | 2022 | |
| Smith+Nephew, INC. | $353.34 | 2024-2025 | Grafix Pl, Oasis, Stravix Pl |
| Medtronic, INC. | $175.97 | 2025 | Intellis Adaptivestim, Vanta Adaptivestim |
| Abbvie INC. | $165.87 | 2021-2024 | |
| Horizon Therapeutics Plc | $119.78 | 2021 | |
| Ani Pharmaceuticals, INC. | $105.23 | 2024-2025 | Purified Cortrophin Gel |
| Allergan, INC. | $93.78 | 2019 | |
| Lilly USA, LLC | $70.51 | 2022-2024 | Mounjaro |
| Stryker Corporation | $54.49 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.18 | 2022 | |
| Vanda Pharmaceuticals INC. | $49.70 | 2022-2024 | Fanapt |
| Novo Nordisk INC | $47.94 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $45.97 | 2022-2023 | |
| Treace Medical Concepts, INC. | $44.54 | 2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.95 | 2020-2022 | |
| Organogenesis INC. | $38.55 | 2022-2023 | Puraply |
| Otsuka America Pharmaceutical, INC. | $38.41 | 2024 | Rexulti, Nuedexta |
| Aimmune Therapeutics, INC. | $35.93 | 2024 | |
| Exact Sciences Corporation | $33.82 | 2023 | Cologuard Collection Kit |
| Uswm, LLC | $29.32 | 2023 | Zimhi, Lucemyra |
| Merck Sharp & Dohme LLC | $28.42 | 2022-2023 | Vaxneuvance, Gardasil 9, Proquad |
| Orthofix Medical, INC. | $20.76 | 2024 | Physio-Stim |
| Musculoskeletal Transplant Foundation INC. | $19.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $18.66 | 2020 | |
| Novartis Pharmaceuticals Corporation | $18.48 | 2022 | |
| Averitas Pharma INC. | $18.29 | 2023 | Qutenza |
| Kci USA, INC. | $16.64 | 2022 | |
| Gilead Sciences, INC. | $15.84 | 2021 | |
| Sanofi Pasteur INC. | $15.03 | 2021 | |
| Bioventus LLC | $12.10 | 2019 | |
| Eisai INC. | $11.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theresa Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.